Aphaia Pharma Reports the P-II Study Results of APHD-012 Among Pre-Diabetic Individuals
Shots:
- The P-II study assesses APHD-012 (12g, oral glucose formulation, QD) or APHD-012P vs matching PBO in prediabetic & diabetic adults or healthy individuals (n=~30) for 6wks., followed by 4wks. washout & switching treatments for the next 6wks.
- The OGTT blood glucose levels at 120min. post-challenge reduced from 9.0±6 to 7.9±0.6 mmol/L vs 8.8±0.4 to 8.5±0.6 mmol/L after 6wks. in all of them while 13.2±7 to 11.6±0.5 mmol/L vs 11.4±0.5 to 12.0±0.6 mmol/L was observed in all diabetic patients
- In prediabetic patients, OGTT blood glucose levels reduced from 8.7±4 to 6.8±0.5 mmol/L vs 8.6±0.4 to 8.2±0.6 mmol/L and OGTT AUC 0-120 minutes decreased from 1261±47 to 1163±36 min*mmol/L vs 1250±45 to 1225±53 min*mmol/L. Data from P-II obesity study is expected in H2'24
Ref: Aphaia Pharma | Image: Aphaia Pharma
Related News:- Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
